Prolonged alfoscerate effects in patients with the syndrome of amnestic mild cognitive impairment

Written by Kolykhalov I.V., Gavrilova S.I.

  UDK: 616.894–053.8–085.214.2 | DOI: 10.17238/PmJ1609-1175.2019.1.18–22  Pages: 18–22 | Full text PDF | Open PDF 


Objective: The objective is to assess immediate and delayed effects of three-months course therapy with a drug ‘Cereton’ (Choline alfoscerate) in patients with anamnestic syndrome of mild cognitive impairment (MCI).
Methods: 50 patients with MCI got a three-month course therapy with Cereton (Choline alfoscerate), dosage 1200 mg/day. 15 patients during a year repeated similar course of therapy. Neuropsychological tests were used to evaluate immediate and delayed effects.
Results: Statistically significant improvement is defined according to the majority of psychometric parameters as a result of single course. Though in 7–9 months after the end of therapy the final results of majority of tests worsened, the level of patients’ cognitive functioning remained at higher level as compared to the beginning of the therapy. Getting the refresher course of treatment patients with MCI reached the same level of cognitive functioning which was after the first course of therapy.
Conclusions: With course treatment with Cereton, a significant therapeutic effect was obtained in relation to the cognitive functioning of patients with MCI. The results indicate the promise of further studies of this drug in the framework of prospective therapeutic programs to determine its therapeutic potential in the implementation of preventive therapeutic strategies in individuals with a high risk of Alzheimer›s disease.

Links to authors:

I.V. Kolykhalov, S.I. Gavrilova
Mental Health Research Center (34 Kashirskoye Shosse St. Moscow 115522 Russian Federation)

1. Alesenko A.V., Gavrilova S.I., Gutner U.A. [et al.]. Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers // Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2017. No. 6. P. 21–27.
2. Badalyan O.L., Pogosyan A.S., Savenkov A.A. [et al.]. The use of Neurox and Cereton in the complex therapy of cerebrovascular diseases // Russky Meditsinsky Zhurnal. 2011. Vol. 19, No. 12. P. 764–767.
3. Batysheva T.N., Nesterova O.S., Otcheskaya O.V. [et al.]. Use of Cereton in patients with mild cognitive impairment of vascular genesis // Difficult patient. 2009. No. 4–5. P.10–12.
4. Gavrilova S.I., Alesenko A.V., Kolyhalov I.V. [et al.]. Clinical and biological effects of cereton (choline alfoscerate) in the treatment of mild cognitive impairment of the amnesic type // Psychiatry. 2017. No. 1. P. 5–15.
5. Aleppo G., Nicoletti F., Sortino M.A. [et al.]. Chronic alphaglycerilphosphorylcholine increases inisitol phosphate formation in brain slices and neuronal cultures // Pharmacol. Toxicol. 1994. Vol. 74. P. 95–100.
6. Bachurin S.O., Gavrilova S.I., Samsonova A. [et al.]. Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention // Pharmacol. Res. 2018. Vol. 129. P. 216–226.
7. Ban T.A., Pansarasa R.M., Borra S. [et al.]. Choline alphoscerate in elderly patients with cognitive decline due to dementing illness // New Trends of Clinical Neuropharmacology. 1991. Vol. 5. P. 1–35.
8. Fink H.A., Jutkowitz E., McCarten J.R. [et al.]. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical alzheimer-type dementia: A systematic review // Ann. Intern. Med. 2018. Vol. 168, No. 1. Р. 39–51.
9. Han S.H., Jeong H.B., Park K.Y. [et al.]. P300 latency changes in patients with mild cognitive impairment after taking choline alphoscerate: A preliminary study // eNeurological Sci. 2018. Vol. 11. P. 5–8.
10. Jongsiriyanyong S., Limpawattana P. Mild cognitive impairment in clinical practice: A review article // Am. J. Alzheimers Dis. Other Demen. 2018. Vol. 33, No. 8. Р. 500–507.
11. Khachaturian Z.S., Khachaturian A.S., Thies W. The draft “National Plan” to address Alzheimer's disease – National Alzheimer's Project Act (NAPA) // Alzheimers Dement. 2012. Vol. 8, No. 3. Р. 234–236.
12. Scapicchio P.L. Revisiting choline alphoscerate profile: A new, perspective, role in dementia? // Int. J. Neurosci. 2013. Vol. 123. Р. 444–449. 13 Sigala S., Imperato A., Rizozonelli P. [et al.]. L-alpha-glycerilphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat // Eur. J. Pharmacol. 1992. Vol. 21. Р. 351–358.
14. Traini E., Bramanti V., Amenta F. Choline alphoscerate (alpha- glyceryl-phosphoryl-choline) an old choline- containing phospholipid with a still interesting profile as cognition enhancing agent // Curr. Alzheimer. Res. 2013. Vol. 10, No. 10. P. 1070–1079.
15. Tomassoni D., Catalani A., Cinque C. [et al.]. Effects of cholinergic enhancing drugs on cholinergic transporters in the brain and peripheral blood lymphocytes of spontaneously hypertensive rats // Curr. Alzheimer. Res. 2012. Vol. 9. P. 120–127.


Founded in 1997  |  Editions in a year: 4, Articles in one issue: 30 |  ISSN of print version: 1609-1175  |  Ind.: 18410 (Agency "Rospechat’")  |  Edition: 1000 c.